Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha-lipoic acid (ALA) has been investigated as a potential therapy for Multiple Sclerosis (MS) due to its antioxidant and anti-inflammatory properties. The rationale is based on the role of oxidative stress and inflammation in the pathogenesis of MS. Preclinical studies have demonstrated that ALA can reduce the migration of immune cells into the central nervous system and decrease markers of inflammation in models of MS. In human studies, a few small clinical trials have been conducted, primarily in secondary progressive MS. For instance, a 2017 randomized, double-blind, placebo-controlled pilot trial (n=51) found that 1200 mg/day of ALA over two years was associated with a slower rate of brain atrophy compared to placebo. Some studies also report improvements in biomarkers of inflammation and oxidative stress, but effects on clinical outcomes such as disability progression and relapse rate are less clear and evidence remains limited. The studies to date are generally small and short in duration, and there is not yet enough high-quality evidence to recommend ALA as a standard treatment for MS. The use of ALA in MS is not based on historical or traditional medicine, but rather on emerging, though preliminary, scientific inquiry. Larger, well-designed clinical trials are needed to better establish efficacy and safety in this population.

More about Alpha-Lipoic Acid
More about Multiple Sclerosis

Other ingredients used for Multiple Sclerosis

Other health conditions supported by Alpha-Lipoic Acid

Products containing Alpha-Lipoic Acid